Pharvaris (NASDAQ:PHVS - Get Free Report) shares saw unusually-strong trading volume on Wednesday . Approximately 37,985 shares changed hands during trading, a decline of 19% from the previous session's volume of 47,045 shares.The stock last traded at $17.41 and had previously closed at $17.85.
Analyst Ratings Changes
Separately, JMP Securities increased their price target on shares of Pharvaris from $46.00 to $55.00 and gave the stock a "market outperform" rating in a research report on Friday, January 31st.
Check Out Our Latest Report on Pharvaris
Pharvaris Stock Performance
The firm has a market cap of $903.05 million, a P/E ratio of -6.17 and a beta of -3.08. The company's 50 day moving average is $18.30 and its 200 day moving average is $19.34.
Hedge Funds Weigh In On Pharvaris
Large investors have recently modified their holdings of the business. Public Employees Retirement System of Ohio bought a new position in shares of Pharvaris during the third quarter valued at $57,000. JPMorgan Chase & Co. raised its stake in shares of Pharvaris by 1,125.3% during the fourth quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company's stock valued at $59,000 after acquiring an additional 2,847 shares during the last quarter. Barclays PLC bought a new position in shares of Pharvaris during the third quarter valued at $106,000. KLP Kapitalforvaltning AS bought a new position in shares of Pharvaris during the fourth quarter valued at $111,000. Finally, Legal & General Group Plc raised its stake in shares of Pharvaris by 11.2% during the fourth quarter. Legal & General Group Plc now owns 9,855 shares of the company's stock valued at $189,000 after acquiring an additional 994 shares during the last quarter.
About Pharvaris
(
Get Free Report)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
See Also
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
